FIRST simplified version of the weak score in the real world new diagnosis of the evaluation value of patients with multiple osteoma patients

 人参与 | 时间:2024-02-24 18:07:01
 [] Objective to discuss the evaluation value of the FIRST simplified version of the weak score in the new world of new diagnosis real time news websiteof multiple osteoma.Methods A retrospective analysis from July 1, 2014 to December 31, 2021 treated the clinical data of 131 new diagnosis of multiple new diagnosed multi -myeloma patients.According to the FIRST simplified version of the weak evaluation score, it is divided into weak groups and non -weak groups.Analyze the efficacy of the two groups during the treatment, early (within April), ≥ 3 levels of infection accumulation, mortality within 1 year, and survival.And the sub -group analysis was performed on the basis of patients with boradise.Results of 131 patients were included in analysis. According to the FIRST weak score, the weak group and non -weak group were 50 (38.17%) and 81 cases (61.83%).The effects of weak and non -weak group ≥ very good part (VGPR) have 18 cases (36.00%) and 37 cases (45.68%), respectively. The difference is not statistically significant (P> 0.05);The rates were 26 cases (52.00%) and 27 cases (33.33%), and the mortality rates were 10 (20.00%) and 6 cases (7.41%) within 1 year, and the differences were statistically significant (P <0.05).The weak group (OS) weak group (OS) is obviously lower than the non-weak group, which are 36 months and 81 months (HR: 2.088; 95%CI: 1.205-3.619; P = 0.003).It is significantly lower than non-weak patients, 16 and 34 months (HR = 2.392; 95%CI: 1.748-3.273; P <0.001).In the analysis of 100 cases of boronami inducement, the weak and non -weak groups were 38 (38.00%) and 62 cases (62.00%), respectively.The efficacy of the two groups ≥VGPR was 12 cases (31.58%) and 30 cases (48.39%), and the differences were not statistically significant (P> 0.05); early ≥ 3 infection accumulation rates were 20 cases (52.63%) and 20, respectively.Example (32.26%), the difference is statistically significant (P <0.05), and the mortality rates are 8 cases (21.05%) and 5 cases (8.06%) within one year.The OS weak group is significantly lower than the non-weak group, which are 34 months and 84 months (HR: 3.210; 95%CI: 1.578-6.532; P <0.001).15 and 33 months (HR = 2.478; 95%CI: 1.775-3.460; P <0.001).Conclusion The FIRST simplified version of the weak score is suitable for newly diagnosed patients with multiple osteoma (NDMM) in the real world, which can be used in clinical work. Key wordsBesides  Multiple osteoma  weak  Infect  Prognosis The value of the first simplify frailty scale in assession real-all patients with newly diagnited multiple myeloma [] Objective to Investigate The Predictive Value of the First Simplify Fralicty SCALE IN PATIENTS WITH Newly Diagnosed Multiple MyEeloma in A Real-World Setttttttttttttttt ING.Methods Retrospective Analysis of Clinical Data of 131 Newly Diagnosed Multiple MyEeloma Patients Admitted to the Third Hospital of Shanxi Medical Univ ErsoundFrom July 2014 To December 2021.They Wee Divided Into Frail and Non-Frail Groups According to the First Simplify Scale.the Best Effical Response, Cum ULATIVE INCIDENCE of Early Grade ≥3 Infection, Mortality within 1 year and overallumvital during time,AnalySed in the Two Groups.a Subgroup Analysis Was Alformed for Patients Receiving Bortezomib- Based Regimens.Results WERENTS WREDED In the AN AN AN Alysis, According to the First FIRST FRAILTY Score, 50 (38.17%) and 81 (61.83%) in the frameyAnd Non-FRAILTY Group, Respectively.18 (36.00%) and 37 (45.68%) Achieved ≥Very Good Part Remssion (VGPR) in the Frail and Non-FRAIL Group, Respecc TIVELY, But the Difference WAS Not Statistics Significant (P> 0.05); THE CUMULATIVE Incision of Early (within 4 Months) Grade ≥3 Infections Was 26 (52. 00%) and 27 (33.33%), Respectively, and the 1-Year Mortality Rates Were 10Re 10Re 10 (20.00%) and 6 (7.41%), Respectively, With Statistics of the Frail Group of Frail Groups (OS), On-Frail Group at 36 Versus 81 MONTHS (HR: 2.088; 95%CI: 1.205-3.619; P = 0.003); Median Progression-Free Survival Time Was Significantly Lower in the FRAIL GROUP Than in the Non-Frail Group, 16 and 34months, Respecti vely (HR = 2.392; 95%CI: 1.748-3.273; P <0.001). In the Subgroup Analysis of 100 Cases Treated with Bortezomib Based INDuction Therapy, 38 (38.00%) and 62 (62.00%) Cases Weee in the Frail and Non-Frail Groups , Respectively.the Effical of ≥VGPR WAS 12 (31.58%) and 30 (48.39%) in the frame and non-frailty groups, Respectively, But the Difference Was Not Statistics (P> 0.05); The Cumulating INCIDENCERENCE of Early (within 4 Months) Grade ≥3 Infection WAS 20 (52. 63%) and 20 (32.26%), Respectively, with Statistics of s (P <0.05), and mortality within 1 year was 8 (21.05%) And 5 (8.06%), Respectively, But the Difference WAS Not Statistical Significant (P> 0.05) .median OS WAS SIGNIFICANTLINFER in the FRAIL GROUP THAN In TH E non-Frail Group, 34 and 84MONTHS, Respectively (HR: 3.210; 95%CI: 1.578-6.532; P<0.001);median progression-free survival time was significantly lower in the frail group than in the non-frail group,15 and 33months,respectively (HR=2.478;95%CI:1.775-3.460;P<0.001). Conclusion The FIRST simplified frailty scale is applicable to real-world newly diagnosed multiple myeloma (NDMM) patients and can be used in clinical practice. 顶: 38713踩: 2853